Our finding that many miRNAs are differentially regulated in the ER mutant breast cancer setting suggests that the direct targeting of these miRNAs through mimics and inhibitors could also represent a promising therapeutic approach in treating this hormone therepy-resistant disease. The gene discussed is ESR1; the disease is breast cancer.